 Radioimmunotherapy (RIT) involves the use of radioactively-conjugated murine antibodies against cellular antigens.Most research involves their application to lymphomas, as these are highly radio-sensitive malignancies.To limit radiation exposure, murine antibodies were chosen, as their high immunogenicity promotes rapid tumor clearance.